Multiple KRAS targeting strategies paving way for combination therapies
KRAS-mutated tumors were once untreatable. In fact, KRAS was something of a poster child for so-called undruggability. Several laboratories are investigating strategies to address other mutations and uses beyond non-small cell lung cancer (NSCLC) and colorectal cancer. If you cant bind KRAS to block it, use a glue or combine multiple weapons. This is the idea behind two new approaches that target cancers caused by this proto-oncogene.
Kras G12c Pan Kras Cyclophilin A Cd8t Cells University Of Texas Md Anderson Cancer Center Memorial Sloan Kettering Cancer Center
Source: bioworld.com